國家衛生研究院 NHRI:Item 3990099045/6889
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 857266      Online Users : 349
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/6889


    Title: Overexpression of galectin-9 in islets prolongs grafts survival via downregulation of Th1 responses
    Authors: Chou, FC;Kuo, CC;Wang, YL;Lin, MH;Yen, BL;Chang, DM;Sytwu, HK
    Contributors: Institute of Cellular and Systems Medicine
    Abstract: The differential activation of T helper (Th) cells and production of cytokines contribute to graft rejection or tolerance. In general, the Th1-type cytokines and cytotoxic T cells are detected consistently in host undergoing rejection, whereas Th2 responses are linked to a tolerance condition. Galectin-9 modulates Th1 cell immunity by binding to the T-cell immunoglobulin mucin-3 (Tim-3) molecule expressed on the Th1 cells. We investigate whether overexpression of galectin-9 in islets prolongs grafts survival in diabetic recipients. Islets were transduced with lentiviruses carrying galectin-9 and were then transplanted to streptozotocin-induced diabetic NOD/SCID recipients. The normoglycemic recipients then received splenocytes from diabetic NOD mice. Blood glucose concentration was monitored daily after adoptive transfer. The histology of the islet grafts and flow cytometric analyses were assessed at the end of the study. Overexpression of galectin-9 in islets prolonged grafts survival in NOD/SCID mice after challenge with diabetogenic splenocytes (mean graft survival, 38.5 vs 26.0 days, n = 10, respectively; P = 0.0096). The galectin-9-overexpressed grafts showed decreased infiltration of IFN-gamma-producing CD4(+) and CD8(+) T cells, but not of IL-17-producing CD4(+) T cells. Strikingly, this islet-specific genetic manipulation did not affect the systemic lymphocyte composition, indicating that galectin-9 may regulate T cellmediated inflammation in situ. We demonstrate that galectin-9 protects grafts from Th1- and Tc1-cell-mediated rejections, suggesting that galectin-9 has preventive and/or therapeutic benefit in transplant therapy for autoimmune diabetes and may be applied further to the transplantation of other organs or tissues.
    Date: 2013-11
    Relation: Cell Transplant. 2013 Nov;22(11):2135-2145.
    Link to: http://dx.doi.org/10.3727/096368912x657891
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0963-6897&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000327109200014
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84886424649
    Appears in Collections:[Betty Lin-Ju Yen] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PB2012120602.pdf487KbAdobe PDF604View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback